1. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

   • Peter Ellmark
   • Sara M. Mangsbo
   • Thomas H. Tötterman

   Review Open access 06 October 2016 Pages: 1 - 7

   

2. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma

   • Andrew Zloza
   • Neal D. Dharmadhikari
   • Howard L. Kaufman

   Original Article 18 October 2016 Pages: 9 - 16

   

3. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma

   • Wataru Obara
   • Takashi Karashima
   • Tomoaki Fujioka

   Original Article Open access 18 October 2016 Pages: 17 - 24

   

4. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

   • Young Kwang Chae
   • Lauren Chiec
   • Francis Giles

   Original Article 19 October 2016 Pages: 25 - 32

   

5. Heterogeneity of CD8⁺ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies

   • Joseph M. Obeid
   • Nolan A. Wages
   • Craig L. Slingluff Jr.

   Original Article 21 October 2016 Pages: 33 - 43

   

6. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report

   • Taofeek K. Owonikoko
   • Mukesh Kumar
   • Suresh S. Ramalingam

   Original Article 22 October 2016 Pages: 45 - 50

   

7. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status

   • John P. Veluchamy
   • A. Marijne Heeren
   • Tanja D. de Gruijl

   Original Article Open access 25 October 2016 Pages: 51 - 61

   

8. Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice

   • Jonathan M. Eby
   • Levi Barse
   • I. Caroline Le Poole

   Original Article 27 October 2016 Pages: 63 - 75

   

9. Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs)

   • Enrique Podaza
   • Florencia Sabbione
   • Mirta Giordano

   Original Article 28 October 2016 Pages: 77 - 89

   

10. Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

    • Maria Winqvist
    • Fariba Mozaffari
    • Jeanette Lundin

    Original Article Open access 04 November 2016 Pages: 91 - 102

    

11. Immunological effects of a novel RNA-based adjuvant in liver cancer patients

    • Luisa Circelli
    • Annacarmen Petrizzo
    • Luigi Buonaguro

    Original Article 10 November 2016 Pages: 103 - 112

    

12. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series

    • Lavinia Spain
    • Gerard Walls
    • James Larkin

    Original Article 12 November 2016 Pages: 113 - 117

    

13. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy

    • Yayan T. Sundara
    • Marie Kostine
    • Anne-Marie Cleton-Jansen

    Original Article Open access 16 November 2016 Pages: 119 - 128

    

14. A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents

    • Sylvia Herter
    • Laura Morra
    • Marina Bacac

    Original Article Open access 17 November 2016 Pages: 129 - 140